Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AME and Bioavailability of LY3866288 in Healthy Participants
NCT06644378Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2024
- Primary completion
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of vepugratinib in solid tumor (advanced stage) and urothelial carcinoma (UC) (2 arms), sponsored by Eli Lilly and Company. Primary endpoints: Fraction of [14C]-LY3866288 Dose Excreted in Urine at Day 21, Fraction of [14C]-LY3866288 Dose Excreted in Feces at Day 21 and 1 more. Started Oct 2024; status: completed.
02
Drugs
vepugratinib
03
Conditions
solid tumor (advanced stage)urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT06644378.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06644378.